Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...
Recursion Pharmaceuticals, Inc () has held its Q3 earnings call. Read on for the main highlights of the call. Recursion Pharmaceuticals Earnings Call Highlights Clinical Momentum ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
With at least seven of its programs expected to begin human trials or read out clinical data during 2025, artificial intelligence (AI)-based drug developer Recursion Pharmaceuticals says it has begun ...
The latest update is out from Recursion Pharmaceuticals ( (RXRX) ).
Recursion Pharmaceuticals RXRX reported a loss of 22 cents per share in the third quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 24 cents. The company had incurred a loss of ...
Recursion Pharmaceuticals also said it plans to prioritize treatments for rare diseases within its pipeline while seeking drugmaker partnerships in areas including immunotherapy, oncology, aging and ...
Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated ...
Recursion Pharmaceuticals Inc. announced Thursday that Sanofi has selected the first development candidate under their research collaboration, triggering a $10 million milestone p ...